SFM
RIGL icon

Sphera Funds Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Sphera Funds Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-122,813
Closed -$1.78M – 121
2023
Q4 		$1.78M Hold
122,813
– – 0.29% 76
2023
Q3 		$1.33M Hold
122,813
– – 0.24% 72
2023
Q2 		$1.58M Sell
122,813
-65,072
-35% -$880K 0.25% 76
2023
Q1 		$2.48M Sell
187,885
-40,000
-18% -$635K 0.41% 59
2022
Q4 		$3.42M Buy
227,885
+11,626
+5% +$107K 0.73% 36
2022
Q3 		$2.55M Sell
216,259
-36,241
-14% -$490K 0.35% 53
2022
Q2 		$2.85M Buy
+252,500
New +$5.07M 0.31% 35
2014
Q1 		– Sell
-22,910
Closed -$653K – 133
2013
Q4 		$653K Buy
+22,910
New +$672K 0.18% 86

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Sphera Funds Management's RIGL Position: Q1 2024 in Review

Sphera Funds Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2024, closing a stake of 122,813 shares — an estimated $1.78M sold.

Sphera Funds Management first reported a position in RIGL in Q4 2013 and held it in 8 quarters. The position peaked at $3.42M in Q4 2022. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2024.

  • Sphera Funds Management reported no remaining Rigel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Sphera Funds Management sold 122,813 Rigel Pharmaceuticals shares in Q1 2024, an estimated $1.78M.
  • Sphera Funds Management first reported a position in Rigel Pharmaceuticals in Q4 2013 and held it in 8 quarters.
  • Sphera Funds Management's Rigel Pharmaceuticals position peaked at $3.42M in Q4 2022.
  • 117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2024.

Based on Sphera Funds Management's 13F filing for Q1 2024, filed 15 May 2024.